- Тел:
- +7 (499) 324-35-79
- Email:
- alexandervlavrov@gmail.com
ORCID ID: 0000-0003-4962-6947
Researcher ID: 2609610
Scopus ID: 57195433184
РИНЦ ID: 141390
The Laboratory of Genome Editing was organized on January 1, 2019 as a result of the separation of the genome editing group from the Laboratory of Mutagenesis.
ORCID ID: 0000-0002-1558-3048
Researcher ID: 2316190
Scopus ID: 30067895000
РИНЦ ID: 173726
Свидетельство об аккредитации специалиста, Протокол № 64 от 27.04.2022 г.
115522, Moscow, Moskvorechye str., 1, 3rd floor (rooms 306, 308-312, 314, 316)
Phones: +7 (499) 324-3579, +7 (499) 612-9989
ORCID ID: 0000-0003-4962-6947
Researcher ID: 2609610
Scopus ID: 57195433184
РИНЦ ID: 141390
The Laboratory of Genome Editing was organized on January 1, 2019 as a result of the separation of the genome editing group from the Laboratory of Mutagenesis.
The laboratory's efforts are focused on the topic of genome editing, including fundamental research for increasing the level of homologous recombination in CRISPR/Cas9 method, as well as applied research to develop treatment of hereditary monogenic diseases. The following works are carried out in the laboratory: 1) editing the most frequent mutation F508del in CFTR gene for the treatment of cystic fibrosis; 2) editing mutations for the treatment of hereditary forms of myopathies (dysferlinopathies, desminopathies); 3) editing of mutations in Glycogen storage disease type 1a. The laboratory uses the entire modern arsenal of genome editors, including the latest methods – base editors and prime editing.
Cystic fibrosis is one of the most common monogenic diseases. The electrolyte composition in the extracellular medium is disturbed due to mutations in the gene of the channel protein for chlorine ions (CFTR), so results to disruption of many organs. Pulmonary symptoms are dominant clinical features. Lungs’ pathology determines the prognosis and survival of the patients. Etiology-based therapy of this disease does not exist. Developed technologies of highly efficient target genome editing allow us to hope that such therapy will be worked out in the near future for many hereditary diseases. Using the technology of targeted nucleases CRISPR/Cas9, we are developing a method for correcting the most frequent mutation p.F508del in cystic fibrosis.